Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кодиак Байосайенсес, Инк.filedCriticalКодиак Байосайенсес, Инк.
Priority claimed from PCT/US2020/024023external-prioritypatent/WO2020191361A2/en
Publication of EA202192504A1publicationCriticalpatent/EA202192504A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicinal Preparation
(AREA)
Abstract
Изобретение относится к внеклеточным везикулам (ВВ), например экзосомам, содержащим полезную нагрузку (например, антиген, адъювант и/или иммуномодулятор) и/или нацеливающий фрагмент. В данном документе также предложены способы получения ВВ (например, экзосом) и способы применения ВВ (например, экзосом) для лечения и/или предупреждения развития заболеваний или нарушений, например рака, болезни "трансплантат против хозяина" (БТПХ), аутоиммунных заболеваний, инфекционных заболеваний или фиброзных заболеваний.The invention relates to extracellular vesicles (EVs), such as exosomes, containing a payload (eg, antigen, adjuvant and/or immunomodulator) and/or targeting fragment. Also provided herein are methods of making EVs (eg, exosomes) and methods of using EVs (eg, exosomes) to treat and/or prevent diseases or disorders such as cancer, graft-versus-host disease (GVHD), autoimmune diseases, infectious diseases or fibrotic diseases.
EA202192504A2020-03-022020-03-20
EXTRACELLULAR VESICLES FOR VACCINE DELIVERY
EA202192504A1
(en)
Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor.their use in the treatment of cancer.
Immuno-stimulating peptide derived from HMGB1 is more effective than the N-terminal domain of Gp96 as an endogenous adjuvant for improvement of protein vaccines